Hansoh Biomedical R&D Company
Clinical trials sponsored by Hansoh Biomedical R&D Company, explained in plain language.
Research and development arm of a major Chinese pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for stomach cancer: targeted drug HS-20093 enters human trials Results expected Dec 2026 (estimated)
- New drug HS-20110 enters human testing for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New hope for tough ovarian cancer: HS-20089 takes on chemo in major trial Results expected Mar 2027 (estimated)
-
Two-Drug combo takes aim at Hard-to-Treat lung cancer
Disease control Not yet recruitingResearchers are testing whether adding the immunotherapy adebrelimab to HS-20093 (risvutatug rezetecan) works better than HS-20093 alone in adults with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated and has no actionable gene changes.…
Phase 2 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combination tested against standard chemo for recurrent ovarian cancer
Disease control Not yet recruitingThis phase III trial compares an experimental drug, HS-20089, given with bevacizumab against standard platinum-based chemotherapy plus bevacizumab in women with platinum-sensitive recurrent ovarian cancer. About 460 participants will be randomly assigned to one of the two treatme…
Phase 3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for tough esophageal cancer: HS-20093 enters final trial
Disease control Not yet recruitingThis Phase 3 trial tests a new drug called HS-20093 against standard chemotherapy in 494 people with advanced esophageal cancer that has worsened after initial treatment. The goal is to see if HS-20093 helps people live longer and controls the tumor better. Participants will rece…
Phase 3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for lung cancer patients: combo therapy enters phase 3 trial
Disease control Not yet recruitingThis phase 3 study tests whether a new combination of drugs (HS-20093 plus adebrelimab) works better than the standard chemotherapy docetaxel for people with advanced or metastatic non-squamous non-small cell lung cancer that has already been treated. The trial plans to enroll 45…
Phase 3 • Sponsor: Hansoh BioMedical R&D Company • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC